Saturna Capital Corp Crispr Therapeutics Ag Transaction History

Saturna Capital Corp

$7.5 Billion
Q3 2024

A detailed history of Saturna Capital Corp transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Saturna Capital Corp holds 9,779 shares of CRSP stock, worth $395,853. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,779

Previous 9,779 -0.0%

Holding current value

$395,853

Previous $528,000 13.07%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$51.17 - $68.18 $58,896 - $78,475	-1,151 Reduced 10.53%	9,779 $528,000
Q4 2023 Feb 06, 2024	BUY	$38.62 - $72.18 $422,116 - $788,927	10,930 New	10,930 $684,000
Q2 2023 Aug 04, 2023	BUY	$43.47 - $67.77 $162,273 - $252,985	3,733 New	3,733 $209,000
Q4 2021 Feb 09, 2022	SELL	$70.09 - $111.29 $131,769 - $209,225	-1,880 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$110.2 - $156.64 $11,020 - $15,663	100 Added 5.62%	1,880 $210,000
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $179,495 - $288,164	1,780 New	1,780 $288,000
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $1.44 Million - $2.73 Million	-13,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $95,604 - $207,876	-1,200 Reduced 8.45%	13,000 $1.99 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $546,700 - $1.08 Million	14,200 New	14,200 $1.04 Million
Q1 2020 May 14, 2020	SELL	$33.68 - $62.53 $114,512 - $212,602	-3,400 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $124,712 - $248,641	3,400 New	3,400 $207,000

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Saturna Capital Corp with notifications on news.

Account

Saturna Capital Corp Crispr Therapeutics Ag Transaction History